|Articles|November 14, 2018
CSF-1 drops demonstrate efficacy, safety in clinical studies for treatment of presbyopia
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Advertisement
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
2
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
3
Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze
4
From detection to decision-making: Navigating disease progression and treatment in geographic atrophy
5




















